Vasilev, K., Hoxie, I., Puente-Massaguer, E. et al. Immunogenicity and protective efficacy of an intranasal neuraminidase-based influenza vaccine with bacterial cell membrane-derived adjuvants. npj Vaccines 10, 149 (2025)
Development of mucosal influenza virus vaccines which protect the site of viral entry is of high importance. Recombinant neuraminidase (NA) has emerged as an antigenically conserved intranasal vaccine candidate, capable of inducing broad cross-protection, but it requires effective mucosal adjuvants. Here, we analyze the immunogenicity and protective efficacy of a mucosal recombinant NA-based influenza virus vaccine adjuvanted with the outer membrane proteins from Neisseria meningitidis complexed with exogenous lipopolysaccharides (LPS) from Shigella flexneri or endogenous LPS from N. meningitidis. We observed increased follicular T-helper and germinal center B-cell population percentages in nasal-associated lymphoid tissue, enhanced IgA and IgG antibody responses, and accumulation of lung-resident memory T cells. The vaccine provided complete protection against homologous and partial protection against a heterologous influenza virus (clade 2.3.4.4b H5N1) challenge. These findings underscore the potential of bacterial membrane-derived adjuvants for developing robust mucosal influenza vaccines.
See Also:
Latest articles in those days:
- Weekly US Influenza Surveillance Report: Key Updates for Week 45, ending November 14, 2026 12 hours ago
- Anatomical Compartmentalization in Chickens Drives Divergent H9N2 Influenza Evolution Toward Human Receptor Binding and Immune Escape 1 days ago
- Epidemiologic Variability and Clinical Severity Across 11 Influenza Seasons in Children 2 days ago
- Molecular Epidemiology of Clade 2.3.4.4b H5N1 High-Pathogenicity Avian Influenza in South Africa, 2025-2026 2 days ago
- Structural basis of avian-to-human receptor-binding adaptation in H9Ny influenza A virus hemagglutinin 2 days ago
[Go Top] [Close Window]


